Landmark lipid-lowering trials in the primary prevention of cardiovascular disease

Clin Cardiol. 2013 Sep;36(9):516-23. doi: 10.1002/clc.22147. Epub 2013 May 30.


Although atherosclerotic cardiovascular disease (CVD) is the most common cause of morbidity and mortality in the world, the long disease latency affords ample opportunity for preventive care. Indeed, lifelong exposure to atherogenic apoliprotein B-containing lipoproteins has consistently been shown to increase the cumulative risk of suffering a CVD event, including myocardial infarction, stroke, and symptomatic peripheral arterial disease. Over the past 25 years, lipid-lowering therapies have been developed that are proven to not only lower cholesterol, but also to decrease adverse CVD events and CVD mortality. This review will highlight several key clinical trials encompassing several classes of lipid-lowering medications that have provided clinicians with an evidence-based framework for managing their patients' cardiovascular risk.

Publication types

  • Review

MeSH terms

  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / prevention & control*
  • Humans
  • Hypolipidemic Agents / therapeutic use*
  • Lipids / blood
  • Primary Prevention / methods*


  • Hypolipidemic Agents
  • Lipids